Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK5. September 2017|In Portfolio News|By eazee-designstudioThe further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom’s innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate. PrevNext
